Quinupristin/Dalfopristin (PDF Version)

Streptogramin

Gram-positive bacteria. In-vitro data suggests streptogramins possess activity against gram-negative upper respiratory tract pathogens and gram-negative anaerobes.

Mechanism of Action:

Inhibition of mRNA translation by binding to the 50S subunit of bacterial ribosomes.

Pharmacodynamics:

Predominantly independent of concentration once above four times the MIC of common Staphylococci and Streptococci.

Pharmacokinetics: (7.5mg/kg dose at steady state)

Cmax: 3.2 and 7.96mg/L (quinupristin and dalfopristin respectively)

Half-life: 3.07 and 1.04 hours (quinupristin and dalfopristin respectively)

Volume of distribution: 0.45 and 0.24L/kg (quinupristin and dalfopristin respectively)

Adverse Effects:

Venous irritation due to quinupristin/dalfopristin is common. In comparative trials approximately 40% of patients experienced infusion site adverse reactions compared to 25% of comparator treated patients. Increasing the infusion volume or administering the drug via central line may attenuate this reaction.

In two compassionate use studies, arthralgias (9.1%) and myalgias (6.6%) were the most common adverse event related to quinupristin/dalfopristin. Hyperbilirubinemia was documented in up to 25% of quinupristin/dalfopristin treated patients in compassionate use/non-comparative studies.

Dosage:

Intravenous only – available as 500mg (150mg quinupristin and 350mg dalfopristin) and 600mg (180mg quinupristin and 420mg dalfopristin) powder for reconstitution vials

Serious or life-threatening infections associated with vancomycin-resistant Enterococcus faecium – 7.5mg/kg every 8 hours

Complicated skin and skin structure infection caused by methicillin-susceptible S. aureus or S. pyogenes – 7.5mg/kg every 12 hours

Disease state based dosing:

Hepatic failure: Although no dosage official dosage adjustment recommendations exist, pharmacokinetic data in

patients with hepatic cirrhosis (Childs-Pugh class A or B) suggest that dosage adjustments may be necessary.

Renal failure: No dosing adjustments are necessary in patients with renal impairment or patients undergoing peritoneal dialysis.

Contraindications/Warnings/Precautions:

Therapeutic monitoring of cyclosporine levels should be performed when cyclosporine is used concomitantly with quinupristin/dalfopristin.
Following infusion the vein should be flushed with 5% dextrose, and not saline or heparin due to incompatibility concerns.

Drug Interactions:

Quinupristin/dalfopristin is a potent inhibitor of the cytochrome P450 3A4 isoenzyme system. Caution should be exercised and monitoring is suggested when concomitantly administering quinupristin/dalfopristin with drugs that have narrow therapeutic windows and are substrates of the CYP3A4 substrates.

Pregnancy:

Category B: No evidence of risk in humans but studies inadequate.

Brand names/Manufacturer: Synercid/DSM pharmaceuticals (Marketed by Monarch pharmaceuticals)

Synercid^â:

§ United Kingdom, U.S.A., Australia, France, Mexico, Austria, Sweden, Brazil, Switzerland, Israel, Canada, Germany, Netherlands, Italy, Spain, South Africa, Ireland, Hungary, Greece, Czech Republic, and Finland.